Background
==========

Thyroid nodules cancer is the most common endocrine malignancy \[[@b1-medscimonit-26-e924045]\], constituting 2--3% of all new cancers diagnosed each year in the USA, and its incidence worldwide has been steadily increasing for more than 30 years \[[@b2-medscimonit-26-e924045]\]. Thyroid cancer is most frequently diagnosed in females aged 45--55 years, and the risk factors include a personal history of head and neck radiation exposure and a family history of thyroid cancer \[[@b3-medscimonit-26-e924045]\]. Papillary thyroid carcinoma (PTC) accounts for approximately 80% of all thyroid cancer cases \[[@b4-medscimonit-26-e924045]\]. The mainstay of treatment for PTC includes surgery, with postoperative adjuvant radioactive iodine therapy also being applied to some patients. Although the overall prognosis of PTC is usually excellent, there are aggressive subtypes that can cause significant morbidity and even lead to mortality \[[@b5-medscimonit-26-e924045]\], which indicates the need for an accurate knowledge of the prognostic risk factors.

There have been many investigations of the prognostic factors for PTC \[[@b6-medscimonit-26-e924045]--[@b8-medscimonit-26-e924045]\], but almost all of them have used traditional survival-analysis methods when analyzing multiple potential factors, such as the Kaplan-Meier marginal regression analysis of patient survival probability, the log-rank test for comparing survival curves, or the Cox proportional-hazards model. The premise of regression in traditional survival analysis is to assume that the censoring time is independent of the expiration time, which assumes that there is no competing risk present and that the outcome is a single endpoint \[[@b9-medscimonit-26-e924045]\]. However, clinical survival data are often associated with multiple outcomes, which may have a competing relationship. The traditional incidence analysis methods often treat such competing events by censoring, which may overestimate the cumulative incidence \[[@b10-medscimonit-26-e924045],[@b11-medscimonit-26-e924045]\]. These aspects indicate that the competing-risks model should be needed to handle multiple endpoints.

The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) collects cancer incidence data from population-based cancer registries covering approximately 34.6% of the USA population \[[@b12-medscimonit-26-e924045]\]. The aim of the present study was to identify accurate prognostic factors for papillary thyroid adenocarcinoma (PTAC) receiving surgery using a competing-risks model based on data from the SEER database. We also compared the performance of this model with that of a Cox proportional-hazards model in predicting prognostic factors for PTAC.

Material and Methods
====================

Database
--------

Data on patients with PTAC receiving surgery were extracted using the SEER\*Stat software (version 8.3.6). The SEER data set was initiated in 1973 as the main USA population-based cancer registry. This database contains data from many geographic regions and covers information on demographics, staging, treatments, and survival; however, certain specific clinical details are not available \[[@b13-medscimonit-26-e924045]\].

Data collection and analysis
----------------------------

We searched the SEER database for all cases of PTAC registered between 2010 and 2015 using the tumor-site ICD-9 code C73.9 ("Thyroid gland") and the ICD-O-3 "Hist/behave" code 8260/3 ("Papillary adenocarcinoma, NOS"). Another inclusion criterion was surgery being performed. The exclusion criteria were as follows: 1) only autopsy findings being available, 2) not the first malignant primary indicator, and 3) incomplete information on survival time. For all of the included patients, the following information was extracted: sex, age at diagnosis, grade, summary stage (localized, regional, or distant), American Joint Committee on Cancer (AJCC) stage, radiation status, chemotherapy status, regional lymph nodes removal, cause of death, vital status, race, insurance status, marital status, tumor size, and survival time.

The seventh edition of the AJCC staging system was adopted. The final analysis was applied to 8324 eligible surgical PTAC patients. Since the individual patient data in the SEER database are de-identified, it was not necessary to obtain approval from an ethics committee or an institutional review board.

Statistical analysis
--------------------

Categorical data are expressed as frequencies and percentages. Continuous data are showed as mean±standard deviation values. In order to facilitate the analysis of the competing-risks model according to the SEER cause-specific death classification and vital-status recode in the SEER database, all patient follow-up outcomes were divided into the following 3 categories: PTAC-specific death, competing events, and censored events. The cumulative incidence function (CIF) represents the probability of the K-th event before time t and other events: CIF*k*(*t*)=Pr(*T*≤*t*, *D*=*k*) \[[@b14-medscimonit-26-e924045]\]. The CIF was used as univariate analysis to calculate the probability of each event, and Nelson-Aalen cumulative risk curves of the incidence function for PTAC-specific death were calculated and then compared between 2 groups using Gray's test. The Fine-Gray model was performed as multivariate analysis to identify the factors that affect the cumulative incidence of PTAC. The Fine-Gray model is suitable for predicting personal risks, estimating the risk and prognosis of disease, and establishing clinical prediction model. This model can be adapted to analyze the cumulative incidence of focus events \[[@b15-medscimonit-26-e924045]\]. We also analyzed a Cox regression model and compared its results with those of the Fine-Gray model. Finally, multivariate analysis was repeated using age as a covariate over time based on the Bayesian information criterion.

All of data analyses performed in this study were implemented using SAS software (version 9.4, SAS Institute), IBM SPSS software (version 24.0, SPSS, Chicago, IL, USA), and the R package. Probability values of *P*\<0.05 were considered statistically significant, and all tests were bilateral.

Results
=======

Patient characteristics
-----------------------

[Table 1](#t1-medscimonit-26-e924045){ref-type="table"} presents the basic information of the patients. The 8324 eligible surgical PTAC patients were aged 46.16±15.10 years. Most of them were female (n=6240, 74.96%), married (n=5335, 64.09%), white (n=6620, 79.53%), and insured (n=7963, 95.66%), and had a well-differentiated grade (n=6776, 81.40%), had localized or regional metastasis (7995, 96.05%), were at AJCC stage I (n=6142, 73.79%), had a tumor size of \<20 mm (n=5687, 68.32%), had either not received chemotherapy or had an unknown chemotherapy status (n=8186, 98.34%), and had their regional lymph nodes removed (n=5251, 63.08%). There were 129 patients who died from other causes, accounting for 1.55% of all of the included patients, while 101 patients died from PTAC (1.21%). The patients who had died from PTAC or other causes tended to be older. The patients who died from PTAC were more likely to be male, separated/divorced/widowed, and American Indian or Native Alaskan, and had distant metastasis, undifferentiated grade, and AJCC stage IV, had received chemotherapy, and had a tumor size of \>40 mm.

Univariate analysis of the prognosis of PTAC
--------------------------------------------

A univariate analysis using Gray's test applied to 12 potential prognostic factors showed that age, sex, marital status, metastasis, differentiation grade, AJCC stage, radiation status, chemotherapy status, regional lymph nodes removal, and tumor size significantly affected the prognosis of the PTAC patients. The Nelson-Aalen cumulative risk curves for variables in multiple categories are shown in [Figure 1](#f1-medscimonit-26-e924045){ref-type="fig"}. For most variables, the CIF increased over 1, 3, and 6 years, and was higher for distant metastasis, undifferentiated grade, receiving chemotherapy, larger tumors, and AJCC stage IV. The CIF values among the patients with the undifferentiated grade were 38.6%, 43.5%, and 46.1% at 1, 3, and 6 years, respectively. The results from the univariate analysis and CIF values are listed in detail in [Table 2](#t2-medscimonit-26-e924045){ref-type="table"}.

Results from the multivariate analysis
--------------------------------------

The factors that were statistically significant (*P*\<0.05) in the univariate analysis were included in the Fine-Gray model. The results showed that age, sex, metastasis, differentiation grade, radiation status, chemotherapy status, and tumor size were independent risk factors for the prognosis of the PTAC patients.

The results of the univariate Cox regression analysis were similar to those of the univariate analysis performed using Gray's test. The factors that were statistically significant in the univariate Cox regression analysis (*P*\<0.05) were included in the multivariate Cox regression analysis. The results showed that marital status was an independent risk factor in addition to age, sex, metastasis, differentiation grade, radiation status, chemotherapy status, and tumor size. The results obtained in the multivariate analyses of the Fine-Gray model and using Cox regression are presented in [Table 3](#t3-medscimonit-26-e924045){ref-type="table"}.

Due to the prognostic factor of age changing in the observation period and causing variations in other prognostic factors, the age was used as a time-varying covariate to repeat the results of Fine-Gray model analysis. The statistically significant factors affecting PTAC when age was used as a time covariate were poorly differentiated grade \[versus well-differentiated grade: hazard ratio (HR)=6.070, 95% confidence interval (CI)=3.339--11.034\], undifferentiated grade (versus well-differentiated grade: HR=8.010, 95% CI=3.689--17.394), no chemotherapy (versus receiving chemotherapy: HR=0.268, 95% CI=0.131--0.548), unknown chemotherapy status (versus receiving chemotherapy: HR=3.518, 95% CI=2.890--41.743), AJCC stage IV (versus stage I: HR=3.583, 95% CI=1.172--10.956), regional metastasis (versus localized: HR=2.577, 95% CI=1.497--19.478), and distant metastasis (versus localized: HR=3.518, 95% CI=2.890--41.743). Neither the linear term (*P*=0.65) nor the quadratic term (*P*=0.67) expressing the interaction of time with age was statistically significant. The data are provided in detail in [Table 4](#t4-medscimonit-26-e924045){ref-type="table"}.

Discussion
==========

This study aimed to identify accurate prognostic factors for PTAC-specific death using a competing-risks model based on data in the SEER database. We found that being older, male, having regional or distant metastasis, a worse differentiation grade, not receiving radiation therapy, receiving chemotherapy, and having a larger tumor are the independent risk factors for PTAC-specific death.

Deaths from PTAC and other causes are not independent, since the former cannot happen once the latter has occurred. This situation is inconsistent with the assumptions underlying Cox regression, and so applying Cox regression might produce incorrect HR values or even inaccurate information about the impact of a single factor. The results obtained in the traditional Cox regression differed from those obtained using a competing-risks model in this study. Although the risk factors identified using the Cox regression model did not differ markedly from those revealed using the competing-risks model, their HR values were different. In addition, marital status was found to be a prognostic factor in Cox regression, with being separated/divorced/widowed increased the risk of death in PTAC patients compared with being married.

Age is a factor that changes with time and may cause variations in other prognostic factors. Tran et al. found that age affects the prognostic impact of tumor size in PTC \[[@b16-medscimonit-26-e924045]\], and so age was treated as a time covariate in the present study, which revealed that after excluding the effects of age, worse differentiation grade, receiving chemotherapy, higher AJCC stage, and metastasis still increase the risk of PTAC-specific death. Tumor size was not included in the competing-risks model with age as a time covariate, but we speculate that there are significant interactions between age and tumor size.

Most previous studies have found male sex to be a significant prognostic factor for a poor outcome in PTC \[[@b17-medscimonit-26-e924045]--[@b19-medscimonit-26-e924045]\]. A meta-analysis found that being male was a very powerful prognostic factor, with increasing the recurrence risk by up to 50%. Its power was even bigger than age \[[@b17-medscimonit-26-e924045]\]. However, contradictory results have also been reported. Oyer et al. reported that being male was not a recurrence risk factor in patients older than 45 years old with differentiated thyroid carcinoma \[[@b20-medscimonit-26-e924045]\]. In addition, Nilubol et al., using the data of SEER database, actually found that being male was not an independent prognostic factor for thyroid follicular cells \[[@b21-medscimonit-26-e924045]\]. These conflicting results may be due to differences in the pathological types of thyroid cancer. Indeed, Lee et al. found that male sex was a poor prognostic factor in PTC but not in papillary thyroid microcarcinoma \[[@b22-medscimonit-26-e924045]\]. In the present study we found that although there were more females than males with PTAC, males had a higher risk of death than females in the competing-risks model. We speculate that the effect of being male on the prognosis of thyroid cancer is greatly affected by the underlying pathology, and that this effect may interact with age.

It should be noted that our study mainly targeted patients with thyroid cancer after surgery, which was due to most patients with thyroid cancer first receiving surgical treatment. Some patients do not receive surgery for various reasons. Ho et al. used SEER data to investigate the mortality risk of nonoperative PTC. They stratified patients into nonsurgical and surgical management, and found that increasing age and tumor size lead to a progressively higher mortality risk without surgery, but only beyond thresholds of age \>56 years and tumor size \>6.1 mm \[[@b23-medscimonit-26-e924045]\]. Feng et al. also found that not receiving surgery was a risk factor for PTC-specific mortality among patients younger than 55 years. Surgery might therefore be appropriate for PTC patients regardless of age \[[@b24-medscimonit-26-e924045]\].

Few studies have researched the prognostic factors for PTAC, with most research focusing on PTC and applying Cox regression models. These studies have found that the significant factors include age \[[@b25-medscimonit-26-e924045]\], multifocality \[[@b26-medscimonit-26-e924045]\], metastases \[[@b27-medscimonit-26-e924045]\], extrathyroidal extension \[[@b28-medscimonit-26-e924045]\], tumor size, and certain genes \[[@b29-medscimonit-26-e924045]\]. While some potentially important variables are not included in the SEER database, our results obtained using a Cox regression model of the prognosis factors for PTAC are basically consistent with the literature reports on PTC. It should also be noted that only relatively minor differences were found for the risk factors between our competing-risks model and the Cox regression model. This might be due to PTAC having a lower risk of death. However, when a competing event exists, it is more accurate to use competing-risk models to analyze prognostic factors, both for risk factors and their HRs.

The limitations of this study cannot be ignored. Firstly, thyroid cancer is a disease with a high recurrence rate, indicating the importance of studying the risk of recurrence; however, this variable is not collected in the SEER database. Another limitation is the relatively short follow-up period (2010--2015). Because the overall prognosis of PTAC is generally favorable, the incidence of PTAC-specific death is low in a short time. Thirdly, some factors, such as vascular invasion, family history, molecular markers, and other histological findings, were not evaluated in our study.

Conclusions
===========

This study has found that age, sex, metastasis, differentiation grade, radiation status, chemotherapy status, and tumor size are independent risk factors for the postoperative prognosis of patients with PTAC in the presence of competing risks. Our findings may be useful for improving patient prognoses and decision-making when providing individualized treatments.
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###### 

Patients characteristics and demographics.

  Variables                        All (n=8234)    Death to thyroid papillary adenocarcinoma (n=101)   Death to other reasons (n=129)
  -------------------------------- --------------- --------------------------------------------------- --------------------------------
  Age                              46.155±15.101   65.436±14.278                                       64.682±14.988
  Sex                                                                                                  
   Male                            1994            44 (2.207%)                                         56 (2.808%)
   Female                          6240            57 (0.913%)                                         73 (1.170%)
  Marital status                                                                                       
   Married                         5335            59 (1.106%)                                         77 (1.443%)
   Unmarried                       2067            14 (0.677%)                                         23 (1.113%)
   DSW                             832             28 (3.365%)                                         29 (3.486%)
  Race                                                                                                 
   White                           6620            87 (1.314%)                                         103 (1.556%)
   Black                           432             3 (0.6945)                                          10 (2.315%)
   Asian or Pacific Islander       1149            10 (0.87%)                                          14 (1.218%)
   American Indian/Alaska Native   33              1 (3.030%)                                          2 (6.061%)
  Stage                                                                                                
   Localized                       4809            9 (0.187%)                                          72 (1.497%)
   Regional                        3186            44 (1.381%)                                         42 (1.318%)
   Distant                         239             48 (20.084%)                                        15 (6.276%)
  Grade                                                                                                
  6Well differentiated             6776            33 (0.487%)                                         104 (1.535%)
   Moderately differentiated       1220            12 (0.984%)                                         18 (1.475%)
   Poorly differentiated           188             26 (13.830%)                                        5 (2.660%)
   Undifferentiated                70              30 (42.857%)                                        2 (2.857%)
  AJCC                                                                                                 
   I                               6142            10 (0.163%)                                         62 (1.009%)
   II                              356             3 (0.843%)                                          12 (3.371%)
   III                             1052            8 (0.760%)                                          27 (2.567%)
   IV                              684             80 (11.696%)                                        28 (4.094%)
  Radiation                                                                                            
   Yes                             4230            68 (1.608%)                                         56 (1.324%)
   No/unknown                      4004            33 (0.824%)                                         73 (1.8235)
  Chemotherapy                                                                                         
   Yes                             48              25 (52.083)                                         1 (2.083%)
   No/unknown                      8186            76 (0.928%)                                         128 (1.564%)
  Insurance                                                                                            
   Insured                         7963            99 (1.243%)                                         125 (1.570%)
   Uninsured/unknown               271             2 (0.738%)                                          4 (1.476%)
  Regional lymph nodes removal                                                                         
   Yes                             5251            80 (1.524%)                                         80 (1.524%)
   No                              2983            21 (0.704%)                                         49 (1.643%)
  Tumor size                                                                                           
   1--10 mm                        3020            6 (0.199%)                                          35 (1.159%)
   11--20 mm                       2667            15 (0.562%)                                         35 (1.312%)
   21--40 mm                       1887            34 (1.802%)                                         33 (1.749%)
   \>40 mm                         660             46 (6.970%)                                         26 (3.939%)

DSW -- divorced, separated or widowed.

###### 

Univariable competing risk analysis in patients with thyroid papillary adenocarcinoma.

  Variables                        Gray's test   p-Value    Cumulative incidence function           
  -------------------------------- ------------- ---------- ------------------------------- ------- -------
  Age                              626.943       \<0.0001                                           
  Sex                              20.333        \<0.0001                                           
   Male                                                     0.011                           0.02    0.031
   Female                                                   0.005                           0.008   0.013
  Marital status                   35.963        \<0.0001                                           
   Married                                                  0.005                           0.010   0.016
   Unmarried                                                0.003                           0.005   0.011
   DSW                                                      0.018                           0.031   0.048
  Race                             3.387         0.336                                              
   White                                                    0.006                           0.012   0.019
   Black                                                    0.007                           0.007   0.007
   Asian or Pacific Islander                                0.004                           0.005   0.017
   American Indian/Alaska Native                            0.000                           0.000   0.081
  Stage                            733.162       \<0.0001                                           
   Localized                                                0.000                           0.001   0.004
   Regional                                                 0.006                           0.013   0.022
   Distant                                                  0.132                           0.188   0.250
  Grade                            1319.580      \<0.0001                                           
   Well differentiated                                      0.001                           0.004   0.009
   Moderately differentiated                                0.003                           0.009   0.019
   Poorly differentiated                                    0.059                           0.141   0.201
   Undifferentiated                                         0.386                           0.435   0.461
  AJCC                             685.372       \<0.0001                                           
   I                                                        0.000                           0.001   0.003
   II                                                       0.003                           0.009   0.009
   III                                                      0.004                           0.005   0.013
   IV                                                       0.064                           0.112   0.167
  Radiation                        8.937         0.003                                              
   Yes                                                      0.007                           0.014   0.024
   No/unknown                                               0.005                           0.008   0.011
  Chemotherapy                     1009.614      \<0.0001                                           
   Yes                                                      0.406                           0.557   0.557
   No/unknown                                               0.004                           0.008   0.015
  Insurance                        0.450         0.503                                              
   Insured                                                  0.006                           0.011   0.019
   Uninsured/unknown                                        0.004                           0.009   0.009
  Regional lymph nodes removal     10.382        0.001                                              
   Yes                                                      0.009                           0.014   0.022
   No                                                       0.001                           0.005   0.012
  Tumor size                       224.703       \<0.0001                                           
   1--10 mm                                                 0.001                           0.001   0.004
   11--20 mm                                                0.002                           0.006   0.007
   21--40 mm                                                0.009                           0.016   0.026
   \>40 mm                                                  0.037                           0.062   0.109

DSW -- divorced, separated or widowed.

###### 

Multivariable analysis in patients with thyroid papillary adenocarcinoma.

  Variables                      Fine-Gray regression analysis   COX regression analysis                                       
  ------------------------------ ------------------------------- ------------------------- --------------- ---------- -------- ---------------
  Age                            \<0.0001                        1.052                     1.031--1.073    \<0.0001   1.059    1.039--1.078
  Sex                                                                                                                          
   Male                          Reference                       Reference                                                     
   Female                        0.008                           0.547                     0.351--0.855    0.007      0.554    0.362--0.849
  Marital status                                                                                                               
   Married                       Reference                       Reference                                                     
   Unmarried                     0.734                           1.114                     0.597--2.078    0.605      1.173    0.640--2.150
   DSW                           0.093                           1.631                     0.922--2.884    0.044      1.709    1.016--2.877
  Stage                                                                                                                        
   Localized                     Reference                       Reference                                                     
   Regional                      0.005                           5.671                     1.670--19.260   0.001      6.032    2.065--17.619
   Distant                       0.0004                          10.217                    2.822--36.982   \<0.0001   11.762   3.909--35.390
  Grade                                                                                                                        
   Well differentiated           Reference                       Reference                                                     
   Moderately differentiated     0.685                           1.153                     0.579--2.298    0.693      1.145    0.584--2.246
   Poorly differentiated         \<0.0001                        5.508                     2.709--11.200   \<0.0001   5.419    2.947--9.963
   Undifferentiated              \<0.0001                        7.247                     3.209--16.367   \<0.0001   8.258    4.150--16.434
  AJCC                                                                                                                         
   I                             Reference                       Reference                                                     
   II                            0.366                           2.185                     0.402--11.878   0.336      2.051    0.474--8.865
   III                           0.384                           0.598                     0.188--1.900    0.247      0.513    0.166--1.587
   IV                            0.057                           2.855                     0.969--8.412    0.084      2.465    0.885--6.866
  Radiation                                                                                                                    
   Yes                           Reference                       Reference                                                     
   No/unknown                    0.007                           2.035                     1.220--3.395    0.004      1.998    1.247--3.203
  Chemotherapy                                                                                                                 
   Yes                           Reference                       Reference                                                     
   No/unknown                    \<0.0001                        0.181                     0.087--0.375    \<0.0001   0.199    0.107--0.370
  Regional lymph nodes removal                                                                                                 
   Yes                           Reference                       Reference                                                     
   No                            0.657                           1.148                     0.623--2.117    0.846      1.057    0.604--1.850
  Tumor size                                                                                                                   
   1--10 mm                      Reference                       Reference                                                     
   11--20 mm                     0.040                           2.627                     1.045--6.605    0.045      2.697    1.023--7.110
   21--40 mm                     0.022                           2.833                     1.163--6.896    0.024      2.960    1.151--7.607
   \>40 mm                       0.006                           3.587                     1.446--8.896    0.005      3.829    1.492--9.824

DSW -- divorced, separated or widowed.

###### 

Multivariable analysis by Bayesian Information Criterions for competing risk.

  Variables                    Z           P          HR      95% CI
  ---------------------------- ----------- ---------- ------- ---------------
  Age.t                        0.447       0.65       1.001   0.998--1.003
  Age.t^2^                     −0.423      0.67       1.000   1.000--1.000
  Grade                                                       
   Well differentiated         Reference                      
   Moderately differentiated   0.866       0.39       1.336   0.693--2.576
   Poorly differentiated       5.915       \<0.0001   6.070   3.339--11.034
   Undifferentiated            5.260       \<0.0001   8.010   3.689--17.394
  Chemotherapy                                                
   Yes                         Reference                      
   No/unknown                  −3.609      0.0003     0.268   0.131--0.548
  AJCC                                                        
   I                           Reference                      
   II                          1.588       0.11       3.346   0.753--14.860
   III                         −0.582      0.56       0.690   0.198--2.409
   IV                          2.238       0.025      3.583   1.172--10.956
  Stage                                                       
   Localized                   Reference                      
   Regional                    5.400       0.01       2.577   1.497--19.478
   Distant                     10.983      0.0004     3.518   2.890--41.743
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